Tumour immune characterisation of primary triple-negative breast cancer using automated image quantification of immunohistochemistry-stained immune cells
(2024) In Scientific Reports 14(1).- Abstract
The tumour immune microenvironment (TIME) in breast cancer is acknowledged with an increasing role in treatment response and prognosis. With a growing number of immune markers analysed, digital image analysis may facilitate broader TIME understanding, even in single-plex IHC data. To facilitate analyses of the latter an open-source image analysis pipeline, Tissue microarray MArker Quantification (TMArQ), was developed and applied to single-plex stainings for p53, CD3, CD4, CD8, CD20, CD68, FOXP3, and PD-L1 (SP142 antibody) in a 218-patient triple negative breast cancer (TNBC) cohort with complementary pathology scorings, clinicopathological, whole genome sequencing, and RNA-sequencing data. TMArQ’s cell counts for analysed immune... (More)
The tumour immune microenvironment (TIME) in breast cancer is acknowledged with an increasing role in treatment response and prognosis. With a growing number of immune markers analysed, digital image analysis may facilitate broader TIME understanding, even in single-plex IHC data. To facilitate analyses of the latter an open-source image analysis pipeline, Tissue microarray MArker Quantification (TMArQ), was developed and applied to single-plex stainings for p53, CD3, CD4, CD8, CD20, CD68, FOXP3, and PD-L1 (SP142 antibody) in a 218-patient triple negative breast cancer (TNBC) cohort with complementary pathology scorings, clinicopathological, whole genome sequencing, and RNA-sequencing data. TMArQ’s cell counts for analysed immune markers were on par with results from alternative methods and consistent with both estimates from human pathology review, different quantifications and classifications derived from RNA-sequencing as well as known prognostic patterns of immune response in TNBC. The digital cell counts demonstrated how immune markers are coexpressed in the TIME when considering TNBC molecular subtypes and DNA repair deficiency, and how combination of immune status with DNA repair deficiency status can improve the prognostic stratification in chemotherapy treated patients. These results underscore the value and potential of integrating TIME and specific tumour intrinsic alterations/phenotypes for the molecular understanding of TNBC.
(Less)
- author
- Roostee, Suze
LU
; Ehinger, Daniel LU
; Jönsson, Mats LU ; Phung, Bengt LU ; Jönsson, Göran LU ; Sjödahl, Gottfrid LU ; Staaf, Johan LU
and Aine, Mattias LU
- organization
-
- Division of Translational Cancer Research
- Breast/lungcancer
- LUCC: Lund University Cancer Centre
- Breast/lung cancer (research group)
- Melanoma Genomics (research group)
- Lund Melanoma Study Group (research group)
- Melanoma
- Urology - urothelial cancer, Malmö (research group)
- Urothelial Cancer Genomics (research group)
- Urothelial cancer
- Research Group Lung Cancer (research group)
- publishing date
- 2024-12
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Scientific Reports
- volume
- 14
- issue
- 1
- article number
- 21417
- publisher
- Nature Publishing Group
- external identifiers
-
- scopus:85204023287
- pmid:39271910
- ISSN
- 2045-2322
- DOI
- 10.1038/s41598-024-72306-1
- language
- English
- LU publication?
- yes
- id
- c08be820-fa9d-46fe-837a-c10fa91d428e
- date added to LUP
- 2024-11-13 13:38:11
- date last changed
- 2025-06-12 06:57:15
@article{c08be820-fa9d-46fe-837a-c10fa91d428e, abstract = {{<p>The tumour immune microenvironment (TIME) in breast cancer is acknowledged with an increasing role in treatment response and prognosis. With a growing number of immune markers analysed, digital image analysis may facilitate broader TIME understanding, even in single-plex IHC data. To facilitate analyses of the latter an open-source image analysis pipeline, Tissue microarray MArker Quantification (TMArQ), was developed and applied to single-plex stainings for p53, CD3, CD4, CD8, CD20, CD68, FOXP3, and PD-L1 (SP142 antibody) in a 218-patient triple negative breast cancer (TNBC) cohort with complementary pathology scorings, clinicopathological, whole genome sequencing, and RNA-sequencing data. TMArQ’s cell counts for analysed immune markers were on par with results from alternative methods and consistent with both estimates from human pathology review, different quantifications and classifications derived from RNA-sequencing as well as known prognostic patterns of immune response in TNBC. The digital cell counts demonstrated how immune markers are coexpressed in the TIME when considering TNBC molecular subtypes and DNA repair deficiency, and how combination of immune status with DNA repair deficiency status can improve the prognostic stratification in chemotherapy treated patients. These results underscore the value and potential of integrating TIME and specific tumour intrinsic alterations/phenotypes for the molecular understanding of TNBC.</p>}}, author = {{Roostee, Suze and Ehinger, Daniel and Jönsson, Mats and Phung, Bengt and Jönsson, Göran and Sjödahl, Gottfrid and Staaf, Johan and Aine, Mattias}}, issn = {{2045-2322}}, language = {{eng}}, number = {{1}}, publisher = {{Nature Publishing Group}}, series = {{Scientific Reports}}, title = {{Tumour immune characterisation of primary triple-negative breast cancer using automated image quantification of immunohistochemistry-stained immune cells}}, url = {{http://dx.doi.org/10.1038/s41598-024-72306-1}}, doi = {{10.1038/s41598-024-72306-1}}, volume = {{14}}, year = {{2024}}, }